Radiotherapy with multiple fractions per day in pancreatic and bile duct cancer |
| |
| Authors: | A L Schuster-Uitterhoeve D Gonzalez Gonzalez L E Blank |
| |
| Affiliation: | 1. Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;2. Oregon Eye Consultants, Eugene, Oregon;3. New Jersey Retina, Teaneck, New Jersey;4. Department of Ophthalmology, University of Iowa, Iowa City, Iowa;5. Retina Northwest, Portland, Oregon;6. Oregon Retina, Eugene, Oregon;7. Northern California Retina Vitreous Associates, Mountain View, California;8. Division of Genetics and Metabolic Disease, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania;9. Department of Pediatrics, Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;1. Université Clermont Auvergne, CNRS, Institut de Chimie de Clermont-Ferrand, F-63000, Clermont Ferrand, France;2. Centre National des Etudes Spatiales, 18 avenue Edouard Belin 31 401 Toulouse Cedex 9, France;1. Instituto de Investigación en Recursos Cinegéticos (IREC), CSIC-UCLM-JCCM, 13005, Ciudad Real, Spain;2. Wildlife Ecology & Health Group (WE&H) and Servei d’Ecopatologia de Fauna Salvatge (SEFaS), Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain;3. Environmental Research Institute, University of the Highlands and Islands, Thurso, Scotland, KW14 7JD, UK;4. Department of Biology & Centre for Environmental and Marine Studies (CESAM), University of Aveiro, Campus Universitário de Santiago, 3810-193, Aveiro, Portugal;5. Wildlife Conservation Medicine Research Group (WildCoM), Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain;1. Research Center for Eco-Environmental Sciences, Chinese Academy of Science, Beijing 100085, PR China;2. Beijing Key Lab of Bioprocess, Beijing University of Chemical Technology, Beijing 100029, PR China;3. National Energy R&D Center for Biorefinery, Beijing University of Chemical Technology, Beijing 100029, PR China |
| |
| Abstract: | Twenty patients with pancreatic and bile duct cancer have been treated with external radiotherapy with multiple fractions per day (MFD). All patients had localized disease only. Sixteen patients have been treated with a split-course technique, to a dose of 60 to 70 Gy in 7-8 weeks, four patients had a continuous series of 44 Gy in 19 days. The mean survival was 7.9 months for patients with a pancreatic cancer. Four out of nine patients with pancreatic cancer in whom the tumour was evaluable showed a tumour regression, one out of nine reached a partial remission. The mean survival in the responders was 9.5 months. All patients with pancreatic cancer died of their tumour. Four out of eight patients with bile duct cancer died of their tumour, the mean survival was 10 months. Four patients with bile duct cancer are still alive (10+, 10+, 10+, 11+ months). No serious acute toxicity was seen. Six patients showed gastrointestinal toxicity at 1.5 to 9 months after the end of treatment. All of them could be treated in a conservative way. From the results obtained in this feasibility study, radiotherapy with MFD in pancreatic and bile duct cancer appears to achieve similar tumour response as conventionally fractionated radiotherapy and the observed toxicity of MFD can be considered as acceptable. MFD might be a more appropriate treatment scheme for combination with chemotherapy and radiosensitizers. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
